Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin E Gleave

Showing results (1-10 of 325) with videos related to

Pageof 33
Sort By:
Future Oncology (London, England)|January 22, 2016
PARP inhibition in castration-resistant prostate cancerLucia Nappi, Martin E Gleave
European Urology|January 9, 2019
Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE)Alexander Kretschmer, Martin E Gleave
The Canadian Journal of Urology|March 11, 2003
A meaningful legacy: urologists as Nobel Prize laureatesVladimir Mouraviev, Martin E Gleave
The Journal of Urology|August 14, 2016
Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: ConMartin E Gleave, Laurence Klotz
EMBO Molecular Medicine|March 25, 2018
Co-targeting driver pathways in prostate cancer: two birds with one stoneAmina Zoubeidi, Martin E Gleave
Urologic Oncology|September 11, 2007
Therapeutic options for hormone-refractory prostate cancer in 2007Boris A Hadaschik, Martin E Gleave
Expert Opinion on Biological Therapy|June 4, 2004
Antisense approaches in prostate cancerKim N Chi, Martin E Gleave
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 16, 2014
Good servants, poor mastersLouis-Olivier Gagnon, Martin E Gleave
Asian Journal of Andrology|April 16, 2013
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancerPaul J Toren, Martin E Gleave
EMBO Molecular Medicine|April 22, 2015
Targeting the adaptive molecular landscape of castration-resistant prostate cancerAlexander W Wyatt, Martin E Gleave
Pageof 33

Showing results (1-10 of 325) with videos related to

Sort By:
Pageof 33
Future Oncology (London, England)|January 22, 2016
PARP inhibition in castration-resistant prostate cancerLucia Nappi, Martin E Gleave
European Urology|January 9, 2019
Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE)Alexander Kretschmer, Martin E Gleave
The Canadian Journal of Urology|March 11, 2003
A meaningful legacy: urologists as Nobel Prize laureatesVladimir Mouraviev, Martin E Gleave
The Journal of Urology|August 14, 2016
Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: ConMartin E Gleave, Laurence Klotz
EMBO Molecular Medicine|March 25, 2018
Co-targeting driver pathways in prostate cancer: two birds with one stoneAmina Zoubeidi, Martin E Gleave
Urologic Oncology|September 11, 2007
Therapeutic options for hormone-refractory prostate cancer in 2007Boris A Hadaschik, Martin E Gleave
Expert Opinion on Biological Therapy|June 4, 2004
Antisense approaches in prostate cancerKim N Chi, Martin E Gleave
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 16, 2014
Good servants, poor mastersLouis-Olivier Gagnon, Martin E Gleave
Asian Journal of Andrology|April 16, 2013
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancerPaul J Toren, Martin E Gleave
EMBO Molecular Medicine|April 22, 2015
Targeting the adaptive molecular landscape of castration-resistant prostate cancerAlexander W Wyatt, Martin E Gleave
Pageof 33